Cargando…
Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of th...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047431/ https://www.ncbi.nlm.nih.gov/pubmed/21329500 http://dx.doi.org/10.1186/1752-1947-5-70 |
_version_ | 1782199037833773056 |
---|---|
author | Ceccarelli, Giancarlo d'Ettorre, Gabriella Marchetti, Francesco Rizza, Cecilia Mastroianni, Claudio M Carlesimo, Bruno Vullo, Vincenzo |
author_facet | Ceccarelli, Giancarlo d'Ettorre, Gabriella Marchetti, Francesco Rizza, Cecilia Mastroianni, Claudio M Carlesimo, Bruno Vullo, Vincenzo |
author_sort | Ceccarelli, Giancarlo |
collection | PubMed |
description | INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of the scientific community because both drugs have a good safety profile coupled with potent antiviral activity, and their combined use would avert nucleoside- and ritonavir-related toxicities. CASE PRESENTATION: We describe the case of a 47-year-old, Caucasian woman treated for HIV-1 infection who developed Buffalo Hump during antiretroviral therapy, including raltegravir and unboosted atazanavir. Clinical evaluation and an ultrasonography scan of the cervical region showed a new progressive increase of lipohypertrophy and the results of DEXA confirmed these data. In our patient the worsening of the Buffalo Hump cannot be attributed to hypercortisolism; insulin-resistance, diabetes, dyslipidemia, hyperlactatemia and metabolic syndrome were not present. Moreover, she was not in therapy with antiretroviral drugs that are described as the cause of Buffalo Hump; on the other hand she developed this side effect three months after the switch of the antiretroviral therapy to raltegravir plus unboosted atazanavir. CONCLUSION: Current data indicate that the etiology of HIV-associated Buffalo Hump remains elusive but is likely multifactorial; a possible contributing cause, but not the main cause, could be exposure to antiretroviral drugs. To the best of our knowledge, this is the first report on development of Buffalo Hump in the course of antiretroviral therapy, including the use of these drugs. On the basis of our data we can formulate the hypothesis of a pharmacological pathogenesis that underlies the development of this case of Buffalo Hump in the absence of other risk factors. |
format | Text |
id | pubmed-3047431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30474312011-03-03 Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature Ceccarelli, Giancarlo d'Ettorre, Gabriella Marchetti, Francesco Rizza, Cecilia Mastroianni, Claudio M Carlesimo, Bruno Vullo, Vincenzo J Med Case Reports Case Report INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of the scientific community because both drugs have a good safety profile coupled with potent antiviral activity, and their combined use would avert nucleoside- and ritonavir-related toxicities. CASE PRESENTATION: We describe the case of a 47-year-old, Caucasian woman treated for HIV-1 infection who developed Buffalo Hump during antiretroviral therapy, including raltegravir and unboosted atazanavir. Clinical evaluation and an ultrasonography scan of the cervical region showed a new progressive increase of lipohypertrophy and the results of DEXA confirmed these data. In our patient the worsening of the Buffalo Hump cannot be attributed to hypercortisolism; insulin-resistance, diabetes, dyslipidemia, hyperlactatemia and metabolic syndrome were not present. Moreover, she was not in therapy with antiretroviral drugs that are described as the cause of Buffalo Hump; on the other hand she developed this side effect three months after the switch of the antiretroviral therapy to raltegravir plus unboosted atazanavir. CONCLUSION: Current data indicate that the etiology of HIV-associated Buffalo Hump remains elusive but is likely multifactorial; a possible contributing cause, but not the main cause, could be exposure to antiretroviral drugs. To the best of our knowledge, this is the first report on development of Buffalo Hump in the course of antiretroviral therapy, including the use of these drugs. On the basis of our data we can formulate the hypothesis of a pharmacological pathogenesis that underlies the development of this case of Buffalo Hump in the absence of other risk factors. BioMed Central 2011-02-17 /pmc/articles/PMC3047431/ /pubmed/21329500 http://dx.doi.org/10.1186/1752-1947-5-70 Text en Copyright ©2011 Ceccarelli et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Ceccarelli, Giancarlo d'Ettorre, Gabriella Marchetti, Francesco Rizza, Cecilia Mastroianni, Claudio M Carlesimo, Bruno Vullo, Vincenzo Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
title | Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
title_full | Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
title_fullStr | Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
title_full_unstemmed | Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
title_short | Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
title_sort | development of buffalo hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047431/ https://www.ncbi.nlm.nih.gov/pubmed/21329500 http://dx.doi.org/10.1186/1752-1947-5-70 |
work_keys_str_mv | AT ceccarelligiancarlo developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature AT dettorregabriella developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature AT marchettifrancesco developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature AT rizzacecilia developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature AT mastroianniclaudiom developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature AT carlesimobruno developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature AT vullovincenzo developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature |